

**In the claims:**

In compliance with 37 C.F.R. §1.121 for making amendments, Applicants present all pending claims with status indicators.

Please cancel claim 88 without prejudice to pursue the subject matter of these claims in an application to be filed in the future.

Please add claims 94-103 as follows:

---

C2 --1. to 86. (Canceled) --

--87. (Previously presented) A monoclonal antibody which specifically binds to PSCA of SEQ ID NO. 2. --

--88. (Canceled) --

--89. (Previously presented) A monoclonal antibody of claim 87, which is a human antibody. --

--90. (Previously presented) The monoclonal antibody of claim 87, which is a chimeric antibody. --

--91. (Previously presented) An antibody of claim 87, which binds a portion of Prostate Stem Cell Antigen (PSCA) protein of SEQ ID NO. 2, wherein the portion is selected from the group consisting of:

a. amino acid residues 2 through 50 as described in SEQ ID NO:2;

- C2  
C3
- b. amino acid residues 85 through 123 as described in SEQ ID NO:2;
  - c. amino acid residues 46 through 109 as described in SEQ ID NO:2;
  - d. amino acid residues 18 through 98 as described in SEQ ID NO:2;
  - e. amino acid residues 22 through 99 as described in SEQ ID NO:2;
  - f. amino acid residues 21 through 50 as described in SEQ ID NO:2;
  - g. amino acid residues 46 through 85 as described in SEQ ID NO:2;
  - h. amino acid residues 50 through 64 as described in SEQ ID NO:2;
  - i. amino acid residues 67 through 81 as described in SEQ ID NO:2;
  - j. amino acid residues 21 through 99 as described in SEQ ID NO:2;
  - k. amino acid residues 71 through 82 as described in SEQ ID NO:2;
  - l. amino acid residues 85 through 99 as described in SEQ ID NO:2;
  - m. amino acid residues 18 through 50 as described in SEQ ID NO:2;
  - n. amino acid residues 46 through 98 as described in SEQ ID NO:2; and
  - o. amino acid residues 85 through 98 as described in SEQ ID NO:2. --

--92. (Previously presented) An Fab, F(ab')<sub>2</sub> or Fv fragment of a monoclonal antibody of claim 87. --

--93. (Previously presented) A hybridoma which produces the monoclonal antibody of claim 87. --

--94. (New) An antibody of claim 87, which specifically binds amino acid residues 18 through 98 of SEQ ID NO:2.--

--95. (New) An antibody of claim 87, which specifically binds amino acid residues 21 through 99 of SEQ ID NO:2.--

--96. (New) An antibody that specifically binds to PSCA of SEQ ID NO. 2 and which binds to a cell that expresses PSCA protein and achieves an effect selected from the group consisting of:

- Continue*
- a. kills the cell to which it binds;
  - b. reduces tumor burden;
  - c. is internalized within the cell to which it binds, and/or
  - d. is cytostatic to the cell to which it specifically binds.

--97. (New) An antibody of claim 96 which kills the cell to which it binds.--

--98. (New) An antibody of claim 96 which is internalized within the cell to which it binds.--

--99. (New) An antibody of claim 96 which is cytostatic to the cell to which it binds.--

--100. (New) An antibody of claim 96 which is monoclonal.--

--101. (New) A hybridoma that produces the antibody of claim 100.--

--102. (New) An antibody of claim 96, which is a human antibody.--

--103. (New) An antibody of claim 96, which is a chimeric antibody.--